Summary Local recurrence of colorectal cancer may result from failure to assess accurately the extent of tumour at operation. It has been suggested that peroperative radioimmunolocalisation may improve this assessment. The degree to which this is possible has been studied using a hand-held gamma detecting probe and comparing two '25I-labelled monoclonal antibodies to colorectal tumours. The antibodies were to fetal colonic microvillus membrane (FMID10) and to carcinoembryonic antigen (A5B7). Sixty-nine per cent (9/13) of the FMlDIO and 98% (43/44) of A5B7 labelled tumours took up significant amounts of antibody with a tumour to normal colon ratio of more than 1.5:1. The uptake was significantly better for A5B7 with a median tumour to normal colon ratio of 3.3 (1. al., 1984; Martin et al., 1985; O'Dwyer et al., 1986; Martin et al., 1986; O'Dwyer et al., 1987) . Only 72-76% of tumours in these patients had significant uptake of these antibodies and the mean time needed for adequate concentration of antibody in tumour compared to normal tissue was 16 days.
The cure of colorectal carcinoma is dependent on adequate primary surgery. Failure to appreciate the extent of the tumour may result in inadequate clearance and subsequent local recurrence (Heald & Ryall, 1986; Turnbull et al., 1967) . While multiple frozen sections or cytology may help determine the spread of tumour this is time consuming and not widely practised.
Peroperative radioimmunolocalisation offers an alternative method of assessing the extent of tumour present. Radiolabelled antibodies to colorectal tumours may be administered intravenously preoperatively and then the distribution of antibody determined at operation using a sterile hand-held gamma detecting probe. The technique depends on reliable uptake of antibody by the tumour at a significantly higher rate than the surrounding tissues.
Previous studies have used a mouse monoclonal antibody to a cell surface antigen of mammary carcinoma metastasis (B72.3), and a polyclonal baboon antibody to carcinoembryonic antigen (CEA) (Aitken et al., 1984; Martin et al., 1985; O'Dwyer et al., 1986; Martin et al., 1986; O'Dwyer et al., 1987) . Only 72-76% of tumours in these patients had significant uptake of these antibodies and the mean time needed for adequate concentration of antibody in tumour compared to normal tissue was 16 days.
In order to improve on these results the characteristics of an ideal antibody would be: (a) that it is taken up by all tumour deposits; (b) the uptake should be rapid so that surgery does not have to be delayed; and (c) the antibody should achieve as high a tumour to normal tissue ratio as possible to enable small quantities of tumour to be detected. We have therefore compared two different antibodies in 50 consecutive patients, first to validate the method of peroperative radioimmunolocalisation and second to assess which of these antibodies has the better characteristics.
Patients and methods
Fifty consecutive patients with colorectal carcinoma gave informed consent to enter the trial. Patients received potassium iodide and potassium perchlorate to block thyroid uptake of antibody. Skin testing for allergey to the antibody was carried out as described previously (Begent et al., 1986) . Following this 1 mCi of '25I-labelled antibody was injected intravenously and an attempted curative resection was carried out 4-10 days later. Of the 50 patients studied 24 were male and 26 female. The (Hennigan et al., 1988) . ASB7 This is a mouse monoclonal IgGl antibody to carcinoembryonic antigen (anti-CEA) (Harwood, 1986; Pedley, 1987) 3 x mean) . From all the individual calculations the upper 99% confidence limit of counts over normal bowel was up to 1.5 times the mean count. Therefore in keeping with previous studies (Aitken, 1984) we have taken a ratio of greater than 1.5 times the value over normal colon to indicate a pathologically high concentration of antibody.
Analysis of specimen The marked sites on the specimen were dissected out and divided. Part was weighed and put into a well counter in the laboratory to measure radioactivity as a percentage of the injected dose per kilogram (Pedley, 1987) . The remainder was sent for histological studies, including morphological appearances and immunoperoxidase staining to demonstrate the site of antibody. In order to assess the smallest quantity of tumour that could be detected, four tumours were subdivided into multiple small pieces which were placed in the submucosa of normal colon of the same specimen and counts recorded. The smallest pieces of tumour that gave a count at least 1.5 times that of normal colon were collected and weighed separately.
Statistical analysis
Differences between different groups were analysed using the non-parametric Mann-Whitney U test and results expressed as median and range. The variation of repeated results from one tissue in one patient was normally distributed and therefore parametric statistical analysis of confidence limits and errors were calculated.
Results
All tumours were adenocarcinoma of colon or rectum. There was a preponderance of more advanced tumours with only 10/57 (17%) being Dukes' stage A, although six of these were in the FM ID0 group. Sixty-five per cent of tumours were in the descending colon or rectum and the majority of patients had moderately differentiated tumours (Table I) . Radioactivity uptake by tumours (Table II) . The median tumour:normal colon ratio for FMID1O was 1.85 (0.75-7.7) compared to 3.3 (1.1-13.8) for A5B7 (P<0.001). The individual peroperative results of tumour:normal colon ratio were correlated with the time interval from injection of antibody until laparotomy ( Figure  1 ). The tumour:normal colon ratios for both antibodies were independent of time with significant uptake as little as 70 hours following injection of A5B7.
The one tumour which failed to take up A5B7 in significant amounts was positive on immunoperoxidase staining for CEA and was in a patient with a very high CEA of 2,300ILg-'. The patients whose tumours failed to take up FMIDl0 had normal CEA levels. There was no correlation between peroperative serum CEA, Dukes' stage or histological differentiation and the tumour:colon ratio for either antibody.
Analysis of specimen The minimum weight of tumour detectable experimentally on the specimen depended on the degree of uptake of antibody. With a tumour:colon ratio of 10:1 a mean ± s.e.m. of 30 + 4 ig of tumour could be detected compared to 140 ± 20 Lg when the ratio was only 2:1.
Well counts Excretion of FMID1O was slower than A5B7. At the time of surgery, the median radioactivity of blood in a well counter was significantly higher for patients given FMID1O at 0.95 (0.1-3.6) % of the injected dose per kilogram (%i.d. kg-') compared to only 0.4 (0.04-2.0) for A5B7 (P<0.01) ( Figure  2 ). For FMIDIO patients, the median radioactivity was significantly higher in blood than in tumour (0.95 (0.1-3.6) versus 0.3 (0.06-1.1) %i.d. kg-', P<0.05). However, for A5B7 patients, radioactivity in tumour was higher than in blood as little as 3 days after injection of antibody (median tumour activity 1.4 (0.4-10.5) versus 0.4 (0.04-2.9) %i.d. kg-' for blood P<0.01).
Comparison ofprobe with well counts To assess if the hand-held probe gave comparable readings to the conventional well counter, results of tumour:normal colon ratios of the resected specimen for each method were correlated by linear regression (Figure 3 ). There was a linear correlation with a correlation coefficient r of 0.78 (P<0.001). Time (hours since injection) Figure 2 Using FMlD10 levels of radioactivity antibody were higher in blood (@) than tumour (0) even after 10 days. Using A5B7 levels of radioactive antibody in the tumour exceeded those in blood in as little as 3 days after injection of antibody. A5B7). In all eight patients high counts correlated with tumour being present and, by ensuring resection margins did not demonstrate high uptake of antibody, they were all reported as being clear histologically. Using A5B7 the location of a primary tumour was found in a patient with an impalpable Dukes' A tumour, and a clinically normal distal resection margin which was found to have a high radioactive count was histologically invaded with tumour.
Probe counts were recorded over the root of the mesentery of 20 Dukes' C carcinomas of which 16 had high counts suggestive of lymphatic spread of tumour. The four patients with normal counts all had A5B7. One was the patient who failed to take up antibody into the primary tumour; two others had histological involvement of only 1:8 and 1:15 nodes with the involved node not being in the root of the mesentery and the fourth had 3:6 nodes invaded including the root of the mesentery.
False positives There were three false positives in the A5B7 group: a histologically inflamed but benign lymph node, a benign duodenal ulcer found incidentally at laparotomy and one lateral pelvic wall after excision of a Dukes' C carcinoma of the rectum. Further biopsy of this hot spot showed only benign tissues.
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Discussion
The use of an intra-abdominal cadmium telluride gamma counting probe has been validated as a reliable method of detecting '25I-labelled antibody, and gives good correlation with laboratory results obtained using a well counter. However, the choice of antibody for this technique appears to be critical. Numerous antibodies have been used to localise human and animal colonic cancers (Mach et al., 1980; Pimm et al., 1985; Epenetro et al., 1986; Balantyne et al., 1988) and some authors have suggested that uptake is more dependent on host factors than the characteristics of the antibody (Balantyne et al., 1988 ).
A5B7 appears to represent a significant improvement on all previously used antibodies. The difference in uptake between FMIDIO and A5B7 demonstrates that A5B7 is more appropriate for the specific requirements that we have made, namely that it is taken up into nearly all tumours, within 3 days, with a high tumour:normal colon ratio so that small quantities of tumour can be detected. Previous authors have suggested that a tumour to normal colon ratio of greater than 1.5:1 is indicative of tumour (Aitken et al., 1984) . Using A5B7, 98% of tumours had a ratio of more 300 * w | w w * than 2:1. Using FM IDI0 anti-fetal microvillus antibody only 69% of tumours had a ratio of more than 1.5:1. It is possible that results with FM lD0 would have been better if a longer period had been left between injection of antibody and laparotomy, as even at 10 days there was more radioactivity in blood than in tumour. Other workers using baboon polyclonal anti-CEA anibodies or anti-cell surface antigen antibodies (Aitken et al., 1984; Martin et al., 1985 Martin et al., , 1986 O'Dwyer et al., 1986 O'Dwyer et al., , 1987 have reported similar results to FMlDIO with 72-76% uptake, but they have used a longer interval of up to 21 days between injection and laparotomy. In this series, most additional information was obtained in patients with locally advanced disease and it was felt that a delay of up to three weeks was a disadvantage, particularly where there may be a risk of obstruction. Consequently, the use of FM1DI0 was abandoned after preliminary assessment of 13 tumours. In contrast, A5B7 anti-CEA monoclonal antibody was taken up by 98% of tumours, with good differentiation between tumour and normal tissues possible in as little as 3 days. The only patient who failed to localise the antibody had a serum CEA of 2,300 ytg 1' and it is postulated that in this instance antibody bound to serum CEA rather than tumour CEA. Nevertheless, one patient with a serum CEA of 7,000 fig 1' was still able to localise the antibody in tumour.
With a ratio of tumour:normal colon of 2:1, tumour of the order of 140 Lg can be detected and this is equivalent to the size of a small lymph node. It must be accepted that microscopic residual tumour may not be detected with the probe. However, having removed the bulk of tumour to less than 0.1 g we are investigating the theoretical possibility that where there has been good uptake of antibody into tumour, one might give further doses of antibody as adjuvant therapy either bound to a high dose of radioactivity or to a chemotherapeutic agent (Lederman, 1989) .
The time taken during operation to count radioactivity of the different tissues adds between 5 and 10 min to the procedure. In practice, counts are not taken over all lymph nodes as the factor which might influence surgery is whether the highest nodes or tissues at the resection margins are involved.
This method offers a quick and simple way for the surgeon to obtain information, rather than awaiting the results of multiple frozen sections.
This technique gave information additional to clinical assessment in approximately 20% of patients which is in keeping with other studies. An interesting observation in these patients is that while in two cases this information led to more radical surgery being performed, more conservative procedures were undertaken in eight patients. The benefits therefore need to be assessed not only in reducing local recurrence and long-term survival, but also in preventing unnecessary debilitating procedures for inflammatory rather than neoplastic change. Only long-term follow-up and absence of late local recurrence will confirm this as a benefit.
False positives and false negatives are a concern and more detailed information is being sought in further clinical studies. The false positive over an active duodenal ulcer may be related to the increased blood supply of this inflammatory lesion. The patient is alive and well 2 years after surgery with no sign of recurrence. In this context, the false positive reading over the lymph node in one patient was also related to a tumour with considerable surrounding inflammation histologically. In this series two patients with carcinoma in active ulcerative colitis had significantly higher uptake into tumour than into inflamed tissues, and we therefore conclude that the antibody does not specifically localise to an area of inflammation. The other false positive was in the lateral pelivic wall following anterior resection. Biopsy of this area was histologically clear, but we have given the patient postoperative radiotherapy to the area. Where tumours invaded adjacent structures there was no difficulty in distinguishing malignant disease from inflammatory disease.
While continued studies are necessary to define in whom peroperative radioimmunolocalisation is going to be of greatest benefit, we have both validated the technique and described the use of anti-CEA monoclonal antibody (A5B7) which has significant advantages over both FM1D1O and all previously described antibodies. Results so far suggest that the probability of complete local excision is increased.
